Brexit Talks Must Prioritize Patient Access, Avoid Regulatory Divergence – EFPIA

The European pharmaceutical industry federation EFPIA says that the interests of the patient and access to medicines must remain at the centre of any decisions taken in the context of negotiations over the UK's exit from the EU, and that the United Kingdom and European Union drug regulatory systems must not be allowed to diverge.

The association also expressed concern over the cloud of uncertainty now gathering over investment decisions and business planning.